Market News & Trends
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio, Inc. recently announced the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program…
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. recently announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau…
MoonLake Immunotherapeutics Starts Phase 3 VELA Program of the Nanobody Sonelokimab in Patients With Moderate-to-Severe Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced the first patients have been screened at a US trial site in its global Phase 3 clinical program, VELA, evaluating sonelokimab,…
Ocean Biomedical Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection & Treat Severe Disease
Ocean Biomedical recently announced that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted…
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal & Bulbar Muscular Atrophy
Avenue Therapeutics, Inc. recently announced the completion of the last patient’s final visit in the company’s Phase 1b/2a clinical trial of AJ201 for the treatment…
Veranova & Phorum.AI Partner to Deliver Generative AI Chemistry Optimization to the Pharmaceutical & Biotech Industry
Veranova and Phorum.AI recently announced they are collaborating on next-generation optimization of pharmaceutical manufacturing processes using artificial intelligence (AI). Building on years of research and…
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals, Inc. provided an update from the its ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant…
Enable Injections & Serina Therapeutics Announce Agreement to Develop SER-252 in Combination With enFuse for Advanced Parkinson’s Disease
Enable Injections, Inc. and Serina Therapeutics recently announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s…
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene AG recently presented the company’s proprietary T cell receptor (TCR) discovery process to obtain optimal affinity 3S (sensitive, specific and safe) TCRs at the…
Roquette Unlocks the Power of Flexibility With Launch of New Flex Softgel Capsule Shell System
Roquette recently announced the launch of its new LYCAGEL Flex hydroxypropyl pea starch premix for nutraceutical and pharmaceutical softgel capsules. Built on Roquette’s market-first LYCAGEL pea…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….